TrialCancer immunology, immunotherapy : CII2014

Definition and application of good manufacturing process-compliant production of CEA-specific chimeric antigen receptor expressing T-cells for phase I/II clinical trial.

Ryan D Guest et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.